NCT01976611已完成不适用
Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 402
- 主要终点
- Number of Participants with Adverse Events and Adverse Drug Reactions
研究概览
简要总结
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.
排除标准
- 未提供
结局指标
主要结局
Number of Participants with Adverse Events and Adverse Drug Reactions
时间窗: 4 Years
Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale
时间窗: 4 Years
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in KoreaUrinary IncontinenceUrinary Bladder, OveractiveNCT02010788Allergan523
已完成
不适用
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in KoreaMuscle SpasticityGlabellar LinesHyperhidrosisNCT02043145Allergan727
已完成
4 期
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean PatientsUrinary IncontinenceOveractive BladderNCT02601287Allergan168
已完成
3 期
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential BlepharospasmBlepharospasmNCT00682760Pacific Pharmaceuticals60
已完成
3 期
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderOveractive BladderNCT00311376Allergan416